drugset / Trial / NCT01658995

Management of Etonogestrel Subdermal Implant-related Bleeding

NCT01658995

Phase 3 Completed 82 enrolled Petra M. Casey
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a double-blinded, randomized, prospective placebo-controlled clinical trial to be conducted within the Mayo Clinic and the Mayo Clinic Health System. The goal of the research study is to gather information to determine whether Doxycycline is effective for the treatment of unacceptable bleeding associated with the etonogestrel subdermal implant (ESI), as compared to placebo.

Timeline

Start
2012-09-13
Primary completion
2019-12-30
Completion
2019-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Doxycycline Small molecule 100 mg Oral

Indications

No indication recorded.